Advocacy intelligence hub — real-time data for patient organizations
Dana-Farber Cancer Institute — PHASE2
University of California, San Diego — PHASE1
Kumquat Biosciences Inc. — PHASE2
Ningbo Newbay Technology Development Co., Ltd — PHASE2, PHASE3
Second Affiliated Hospital, School of Medicine, Zhejiang University — PHASE2
The First Affiliated Hospital with Nanjing Medical University — NA
Universität Duisburg-Essen
GlaxoSmithKline — PHASE3
Asan Medical Center — PHASE1, PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Ayvakit
Blueprint
Ayvakit
(avapritinib)Orphan drugBlueprint Medicines Corporation
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Avapritinib is a tyrosine kinase inhibitor that targets KIT D816V, PDGFRA and PDGFRA D842 mutants as well as multiple KIT exo...
Imatinib Mesylate
(IMATINIB)Orphan drugMylan Institutional Inc
12.1 Mechanism of Action Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal...
Imatinib Mesylate
(IMATINIB MESYLATE)Orphan drugstandardApotex Corp
12.1 Mechanism of Action Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal...
Stivarga
(regorafenib)Orphan drugstandardBayer HealthCare Pharmaceuticals, Inc.
12.1 Mechanism of Action Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular fu...
Suzanne George, MD
Dana-Farber Cancer Institute
Global Clinical Leader
Daiichi Sankyo
Neeta Somaiah, M.D
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Antoine Italiano, M.D
Institut Bergonie Cancer Center
📍 Bordeaux, NY
Kristen Ganjoo, MD, MD
Stanford University
📍 STANFORD, CA
George D. Demetri, MD, MD
Dana-Farber Cancer Institute
📍 BOSTON, MA